Intercept Pharmaceuticals’ next-generation FXR agonist INT-787 showed no clear evidence of potential in patients with severe alcohol-associated hepatitis, adding another setback for the company’s liver inflammation pipeline. The failure follows what investors had hoped would be a path toward next development steps after earlier program expectations. The Phase 2 outcome tightens the window for risk-taking in hepatology drug development, where tolerance, efficacy signal clarity, and trial endpoints are being scrutinized aggressively. It also reinforces that the bar for advancement in alcohol-associated hepatitis remains high even for mechanistically targeted FXR programs. For biotech teams evaluating similar mechanisms, the near-term implication is that late Phase 2 readouts can quickly reset expectations for FXR agonist development timelines and partnering discussions.